INMB - INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

2024-04-22 04:27:08 ET

Summary

• INmune Bio is focused on developing drugs for neurology and cancer medicine.
• The company's most advanced product candidate is XPro 1595, which is being developed for Alzheimer's disease.
• INMB's financial situation may require a cash raise by the end of 2024, but there is potential for significant upside if their clinical platforms show positive results.

Topline Summary and Update

INmune Bio ( INMB ) is a company focused on developing drugs in two different disease areas: neurology and cancer medicine. I've previously covered this company in two articles, and I was a cautious optimist in my latest outing , with main reservations related to their cash burn rate and the challenges of developing drugs for Alzheimer disease, which is their most advanced focus. This article is an update providing a picture of how the story has continued to evolve over the past several months, particularly in light of the recent freefall in share valuation that INMB has experienced in the last month, giving back almost all the gains it's made since last November....

For further details see: